Work

Safety, pharmacokinetics, and antitumor activity of MEDI-573, an investigational monoclonal antibody that targets IGF-I and IGF-II, in adult patients with advanced solid tumors.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.tps2618

Authors: Paul Haluska, Michael E. Menefee, Elizabeth R. Plimack, Jonathan E. Rosenberg, Donald W. Northfelt, Theresa LaVallee, Wenmei Huang, Xiang-Qing Yu, Jaye Viner, Patricia LoRusso

Institutions: Mayo Clinic, Mayo Clinic in Florida, Fox Chase Cancer Center, Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Mayo Clinic in Arizona, The Barbara Ann Karmanos Cancer Institute

Language: English

Topic: Growth Hormone and Insulin-like Growth Factors

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2805870641

Cites:

Cited by: 2

Related to: 10